Clinical Significance of Immunohistochemistry in Detecting Epidermal Growth Factor Receptor Mutation in Lung Cancer

YANG Zhenhua; YE Liang; FANG Surong; GU Wei

doi:10.3971/j.issn.1000-8578.2016.04.007

Cancer Research on Prevention and Treatment > 2016 > 43(4): 272-276. > DOI: 10.3971/j.issn.1000-8578.2016.04.007

YANG Zhenhua, YE Liang, FANG Surong, GU Wei. Clinical Significance of Immunohistochemistry in Detecting Epidermal Growth Factor Receptor Mutation in Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2016, 43(4): 272-276. DOI: 10.3971/j.issn.1000-8578.2016.04.007

Citation:

PDF (6820 KB)

Clinical Significance of Immunohistochemistry in Detecting Epidermal Growth Factor Receptor Mutation in Lung Cancer

Department of Respiratory Medicine, Nanjing Hospital Affiliated to Nanjing Medical University, Nanjing 210006, China

More Information

Received Date: November 22, 2015
Revised Date: January 22, 2016

Graphical Abstract

Abstract

Abstract

Objective To explore the clinical value of immunohistochemistry (IHC) in screening the epidermal growth factor receptor(EGFR) mutation in lung cancer patients. Methods The two mutationspecific antibodies targeting the delE746-A750 mutation in exon 19 and L858R mutation in exon 21 were used for IHC, and the method of direct DNA sequencing was served as control. Results In this investigation, we found 3(6.25%) cases scored 0, 11(20.75%) scored 1, 22(81.48%) scored 2, 8(100%) scored 3 assessed by IHC existed EGFR mutation in direct DNA sequencing analysis. When score≤1+ was considered to be negative and score≥2+ to be positive, the agreement between the two different detection methods was highest(κ=0.683), which the sensitivity was 71.43% and specificity was 94.68%. In the same time, the positive predictive value (PPV) was 85.71% and the negative predictive value (NPV) was 88.12%. Conclusion The score of EGFR mutation assessed by IHC≤1 is considered to be negative mutation whereas score≥2 to be positive mutation.
- Immunohistochemistry(IHC),
- Direct DNA sequencing,
- EGFR mutation,
- Lung cancer

FullText(HTML)

References (15)

References

[1]	Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutation in lung cancer[J]. Nat Rev Cancer, 2007, 7: 16 9-81.
[2]	Yu J, Kane S, Wu J, Benedettini E, et al. Mutation-specific antibodies for the detection of EGFR mutation in non-small-cell lung cancer[J]. Clin Cancer Res, 2009, 15(9): 3023-8.
[3]	Kato Y, Peled N, Wynes MW, et al. Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible method for epidermal growth receptor mutations[J]. J Thorac Oncol, 2010, 5(10): 15 51-8.
[4]	Hasanovic A, Ang D, Moreira AL, et al. Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinoma[J]. Lung Cancer, 2012, 77(2): 29 9-305.
[5]	EAmbrosini-Spaltro A, Campanini N, Bortesi B, et al. EGFR mutation-specific antibodies in pulmonary adenocarcinoma: a compa r i son wi th DNA di r e c t s equenc ing[ J ] . Appl Immunohistochem Mol Morphol, 2012, 20(4): 356-62 .
[6]	Kawahara A, Taira T, Azuma K, et al. A diagnostic algorithm using EGFR mutation-specific antibodies for rapid response EGFR-TKI treatment in patients with non-small cell lung cancer[J]. Lung Cancer, 2012, 78(1): 39-44.
[7]	Bai H, Wang Z, Chen K, et al. Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer[J]. J Clin Oncol, 2012, 30(25): 3077-83.
[8]	Zhou Q, Zhang XC, Chen ZH, et al. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer[J]. J Clin Oncol, 2011, 29(24): 3316-21.
[9]	Fan X, Liu B, Xu H, et al. Immunostaining with EGFR mutationspecific antibodies: a reliable screening method for lung adenocarcinomas harboring EGFR mutation in biopsy and resection samples[J]. Hum Pathol, 2013, 44(8): 1499-507.
[10]	Kawahara A, Azuma K, Sumi A, et al. Identification of non-smallcell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry[J]. Lung Cancer, 2011, 74(1): 35-40.
[11]	Jiang GY, Fan CF, Zhang XP, et al. Ascertaining an appropriate diagnostic algorithm using EGFR Mutation-specific antibodies to detect EGFR status in non-small-celllung cancer[J]. PLoS One, 20 13, 8(3): e59183.
[12]	Allo G, Bandarchi B, Yanagawa N, et al. Epidermal growth factor receptor mutation-specific immunohistochemical antibodies in lung adenocarcinoma[J]. Histopathology, 2014, 64(6): 826-39.
[13]	Kitamura A, Hosoda W, Sasaki E, et al. Immunohistochemical detection of EGFR mutation using mutation-specific antibodies in lung cancer[J]. Clin Cancer Res, 2010, 16(13): 3349-55.
[14]	Wu SG, Chang YL, Lin JW, et al. Including total EGFR staining in scoring improves EGFR mutation detection by mutation-specific antibodies and EGFR TKIs respene prediction[J]. PLoS One, 20 11, 6(8): e23303.
[15]	Wen YH, Brogi E, Hasanovic A, et al. Immunohistochemical staining with EGFR mutation-specific antibodies: high specificity as a diagnostic marker for lung adenocarcinoma[J]. Mod Pathol, 20 13, 26(9): 1197-203.

Cited By

Get Citation

PDF

XML

Article views (1325) PDF downloads (592)

Turn off MathJax

Article Contents

Abstract

References

Clinical Significance of Immunohistochemistry in Detecting Epidermal Growth Factor Receptor Mutation in Lung Cancer

Abstract

References

Catalog

Download Center

Links

Contact Us

Clinical Significance of Immunohistochemistry in Detecting Epidermal Growth Factor Receptor Mutation in Lung Cancer

Abstract

References

Catalog

Download Center

Links

Contact Us

Export File

Citation

Format

Content